About Okinawa Pharmaceuticals Private Limited
Data last updated:
Okinawa Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 30 December 2015 and has been in existence for over 11 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51101MH2015PTC306595. Its GSTIN is 36AACCO2479A1ZO (Telangana). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Chandra Sekhara Reddy Eduru and Ramadevi Ananthu.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹14.1 Cr, a growth of 14% compared to the previous year. For the same year it recorded a net profit of ₹58.54 Lakh (net margin 4.2%) and EBITDA of ₹93.09 Lakh (EBITDA margin 6.6%). Revenue has grown at a compounded annual rate (CAGR) of 8% over three years and 18% over five years.
The company has about 32 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹34.01 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website okinawapharma.org.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressUnit No.611 6th Floor Reliables Pride Anand Nagar Jogeshwari W, Est, Mumbai, Maharashtra, India – 400102
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Okinawa Pharmaceuticals Private Limited
The main business activity of Okinawa Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Okinawa Pharmaceuticals Private Limited FY 2025 filings available
Okinawa Pharmaceuticals Private Limited reported revenue of ₹14.1 Cr (up 14% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Okinawa Pharmaceuticals Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 18% over five years, including 14% growth in the latest year. EBITDA rose 38% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Okinawa Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹93.09 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹58.54 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Okinawa Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 6.6% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 4.2% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Okinawa Pharmaceuticals are in the company report.
Financial statements from FY 2016
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Okinawa Pharmaceuticals Private Limited
Okinawa Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Celltricks Biotech Private Limited | ₹14.16 Cr (FY 2024) | •••• | •••• | 38.0% | •••• | Anekal, Karnataka, India |
| Park N Chem Pharmaceuticals Private Limited | ₹14.16 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | Amritsar, Punjab, India |
| Medilife Health Sciences Private Limited | ₹14.13 Cr (FY 2023) | •••• | •••• | -34.0% | •••• | Mumbai, Maharashtra, India |
| Mendine Lifecare Products Private Limited | ₹14.11 Cr (FY 2024) | •••• | •••• | 37.0% | •••• | Kolkata, West Bengal, India |
| Fling Pharmaceuticals Private Limited | ₹14.1 Cr (FY 2024) | •••• | •••• | -21.0% | •••• | Thrissur, Kerala, India |
| Okinawa Pharmaceuticals Private Limited this company | ₹14.1 Cr (FY 2025) | •••• | •••• | 14.0% | •••• | Mumbai, Maharashtra, India |
| Novarc Labs Private Limited | ₹14.09 Cr (FY 2015) | •••• | •••• | •••• | Hyderabad, Telangana, India | |
| SBS Biotech Corporate Private Limited | ₹14.08 Cr (FY 2024) | •••• | •••• | 2.0% | •••• | Ambala Cantt, Haryana, India |
| Cannyco Pharma Private Limited | ₹14.07 Cr (FY 2023) | •••• | •••• | 10.0% | •••• | New Delhi, Delhi, India |
| Elder-Ici Healthcare Private Limited | ₹14.04 Cr (FY 2024) | •••• | •••• | -12.0% | •••• | Daman, Dadra and Nagar Haveli, India |
| Keewel Healthcare Private Limited | ₹14.04 Cr (FY 2025) | •••• | •••• | 18.0% | •••• | Thane, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Okinawa Pharmaceuticals by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Okinawa Pharmaceuticals Private Limited
Auditor information for Okinawa Pharmaceuticals Private Limited provides details about the firm responsible for auditing the company's financial statements and ensuring compliance with regulatory requirements.
Board of Directors of Okinawa Pharmaceuticals Private Limited
Okinawa Pharmaceuticals has 6 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Srujana Bitra Also directs: Costarica Pharmaceuticals Private Limited | Additional Director | 06 Apr 2024 | 2 Years 6 Months | Current |
| Anjaneyulu Boddapati Also directs: Vande Bharat Pharmaceuticals Private Limited | Additional Director | 06 Apr 2024 | 2 Years 6 Months | Current |
| Venkatrao Mandati | Additional Director | 04 Apr 2024 | 2 Years 6 Months | Current |
| Chandra Sekhara Reddy Eduru | Director | 26 Dec 2017 | 8 Years 9 Months | Current |
| Divyakolu Ramanjaneyulu | Additional Director | 04 Apr 2024 | 2 Years 6 Months | Current |
| Ramadevi Ananthu | Director | 30 Dec 2015 | 10 Years 9 Months | Current |
Ownership and Shareholding of Okinawa Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Okinawa Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Apr 2021 | Hdfc Bank Limited | ₹34.01 Lakh | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Okinawa Pharmaceuticals Private Limited
Okinawa Pharmaceuticals Private Limited has a workforce of 32 employees as of Apr 06, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Okinawa Pharmaceuticals Private Limited
Okinawa Pharmaceuticals has one previous CIN (Corporate Identification Number): U51101TG2015PTC102484. The current CIN is U51101MH2015PTC306595, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U51101MH2015PTC306595 | Current |
| U51101TG2015PTC102484 | Previous |
Recent Activity on Okinawa Pharmaceuticals Private Limited
Okinawa Pharmaceuticals Private Limited has 9 board changes on record since 2015: 6 appointments and 3 cessations. The latest: Anjaneyulu Boddapati was appointed as Additional Director on 06 Apr 2024.
1 earlier event is listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Okinawa Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Okinawa Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Okinawa Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Okinawa Pharmaceuticals Private Limited
Okinawa Pharmaceuticals has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AACCO2479A1ZO | Telangana | Active | 01 Jul 2017 |
| 37AACCO2479A1ZM | Andhra Pradesh | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Okinawa Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Okinawa Pharmaceuticals Private Limited
Okinawa Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 30 December 2015 (11+ years old) and is registered under CIN U51101MH2015PTC306595.
Okinawa Pharmaceuticals reported revenue of ₹14.1 Cr for FY 2025 (up 14% YoY).
Okinawa Pharmaceuticals has 6 current directors:
- Srujana Bitra - Additional Director
- Anjaneyulu Boddapati - Additional Director
- Venkatrao Mandati - Additional Director
- Chandra Sekhara Reddy Eduru - Director
- Divyakolu Ramanjaneyulu - Additional Director
- Ramadevi Ananthu - Director
Okinawa Pharmaceuticals reported a net profit of ₹58.54 Lakh (net margin 4.2%) and EBITDA of ₹93.09 Lakh (EBITDA margin 6.6%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Okinawa Pharmaceuticals is 8% over three years and 18% over five years. In the latest year (FY 2025) revenue rose 14%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Okinawa Pharmaceuticals is 36AACCO2479A1ZO, registered in Telangana. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 37AACCO2479A1ZM (Andhra Pradesh).
The CIN (Corporate Identification Number) of Okinawa Pharmaceuticals is U51101MH2015PTC306595. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Okinawa Pharmaceuticals was incorporated on 30 December 2015, making it 11+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Okinawa Pharmaceuticals by revenue are Celltricks Biotech Private Limited, Park N Chem Pharmaceuticals Private Limited, Medilife Health Sciences Private Limited, Mendine Lifecare Products Private Limited, Fling Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals).
Anjaneyulu Boddapati was appointed as Additional Director on 06 Apr 2024. Srujana Bitra was appointed as Additional Director on 06 Apr 2024. Divyakolu Ramanjaneyulu was appointed as Additional Director on 04 Apr 2024. Okinawa Pharmaceuticals has 9 board changes on record in total.
Okinawa Pharmaceuticals can be reached through the website okinawapharma.org. Its registered office is in Mumbai, Maharashtra, India.